US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 24.010
  • -0.270-1.11%
Trading Mar 28 13:41 ET
3.01BMarket Cap-15.01P/E (TTM)

Apellis Pharmaceuticals Key Stats

Apellis Pharmaceuticals Q4 2024 Earnings Date

Currency:USDFeb 28, 2025

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
197.91M
212.53M
+14.61M
Beat Est.
+35.21%
+45.19%
+7.38%
EPS
-0.39
-0.29
+0.10
Beat Est.
+46.83%
+60.27%
+25.28%
Buy

Mar 28, 2025

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 17 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 211.751M--
--2025/Q1-- / 197.605M--
Feb 28, 20252024/Q4212.528M / 197.915M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 211.751M--
--2025/Q1-- / 197.605M--
Feb 28, 20252024/Q4212.528M / 197.915M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

Read more

Market Insights
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Mar 28, 2025

Buy

  • Buy

    63.16%
  • Hold

    36.84%
  • Sell

    0.00%

Price Target

No Data